We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Medical Solutn | LSE:MLS | London | Ordinary Share | GB0009739649 | ORD 2P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 7.72 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jul 2019 to Jul 2024
TIDMSBS
RNS Number : 2236C
Source BioScience PLC
14 October 2015
14 October 2015
Source BioScience plc
(the 'Company')
Director/PDMR Shareholding
Source BioScience plc (LSE:SBS) announces that on 12 October 2015 Laurence Turnbull, Chairman of the Company, sold 2,000,000 ordinary shares of 2 pence each in the Company ("Ordinary Shares") in the market, at a price of 17 pence per Ordinary Share.
Following this transaction, Mr Turnbull has an interest in 2,750,000 Ordinary Shares representing approximately 0.79% of the Company's issued share capital.
This notification is provided in accordance with DTR3.1.4R(1).
--- ENDS ---
For further information, please contact:
Source BioScience plc
Dr Nick Ash, CEO and Company Secretary
Tel: +44 (0)115 973 9010
Email: enquiries@sourcebioscience.com
www.sourcebioscience.com
N+1 Singer (Financial Advisor, Sponsor and Broker)
Aubrey Powell/James White
Tel: +44 (0)207 496 3000
www.n1singer.com
About Source BioScience
Source BioScience plc (LSE: SBS) is a trusted provider of state of the art laboratory services and products to the healthcare and clinical, life and applied sciences and biopharma industries. It is an international business operating ten state of the art facilities in five countries and with customers in over 90 countries worldwide. The Group offers a complementary portfolio of laboratory services and products that share common technologies, laboratory processes, infrastructure and expertise. These include clinical diagnostics, genomics, proteomics, drug discovery and development research as well as controlled environment storage and testing services for a diverse range of markets. These services and products are provided to a large and diverse customer base including the top 50 pharmaceutical companies, leading universities and research institutes worldwide, the UK NHS and other healthcare providers. The Group is listed on the Premium Main Market of the London Stock Exchange.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSFFDSALFISEIS
(END) Dow Jones Newswires
October 14, 2015 04:54 ET (08:54 GMT)
1 Year Medical Solutions Chart |
1 Month Medical Solutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
